There has been an increasing interest in the potential for moving beyond three-drug combinations to improve the treatment of patients with multiple myeloma in the frontline setting. In this activity, Dr. Kumar discusses the rationale, decision making, and trials that explore four-drug combinations for patients with newly diagnosed multiple myeloma. He also explains the efficacy and toxicity burden of these regimens.

It is important to assess age and fitness when formulating management approaches for a patient with multiple myeloma. In this newsletter, Dr. Tuchman explains the optimal method for assessing the impact of aging and the appropriate considerations for evaluating older patients. He also discusses the different geriatric assessments and instruments best suited to assess elderly patients with multiple myeloma.